Merrimack Pharmaceuticals, Inc.
MACK
MACK was delisted on the 17th of May, 2024.
140 hedge funds and large institutions have $467M invested in Merrimack Pharmaceuticals, Inc. in 2016 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 51 increasing their positions, 30 reducing their positions, and 19 closing their positions.
70% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 30
5% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 19
1% more funds holding
Funds holding: 139 → 140 (+1)
34% less capital invested
Capital invested by funds: $703M → $467M (-$236M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
70% less call options, than puts
Call options by funds: $227K | Put options by funds: $754K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$14.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$12.1M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$8.99M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.63M |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
+$6.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$49.2M |
| 2 |
UBS AM
Chicago,
Illinois
|
-$6.71M |
| 3 |
PC
PointState Capital
New York
|
-$2.93M |
| 4 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$2.64M |
| 5 |
VOYA Investment Management
Atlanta,
Georgia
|
-$2.58M |
MACK Hedge Fund Activity: Q2 2016 in Review
140 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q2 2016, worth a combined $467M — down 34% from $703M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new MACK positions and 19 closed out — a net gain of 1 holder — while 51 added to existing stakes and 30 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $14.2M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $49.2M sold.
- 140 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q2 2016, up from 139 in Q1 2016.
- Funds reported $467M of Merrimack Pharmaceuticals, Inc. stock for Q2 2016, down 34% quarter-over-quarter.
- 20 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q2 2016 and 19 closed out, a net change of +1 holder.
- The largest Merrimack Pharmaceuticals, Inc. buyer in Q2 2016 was Millennium Management, an estimated $14.2M added.
- The largest Merrimack Pharmaceuticals, Inc. seller in Q2 2016 was Consonance Capital Management, an estimated $49.2M sold.
Based on aggregated 13F filings for Q2 2016.